BioNTech SE
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-84.1% vs price
Base Case (Median)
-73.8% vs price
Bull Case (75th pct.)
-63.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $5.15 | -94.4% | High (40%) |
| EV/FCF | $42.89 | -53.2% | Medium (20%) |
Based on 2 out of 8 methods, BNTX appears overvalued at the current price of $91.60. The base case fair value of $24.02 implies 73.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.